Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix

More than 2,000 people in the UK are currently living with the genetic bleeding disorder

- PMLiVE

AbbVie expands inflammatory disease pipeline with $250m Celsius acquisition

The deal includes an anti-TREM1 antibody that has completed a phase 1 study in inflammatory bowel disease

- PMLiVE

FDA publishes guidance on diversity action plans to improve enrolment in clinical trials

The guidance will help to enhance the understanding of a disease or medical product being studied

- PMLiVE

Scientists discover new form of gene editing to recombine and rearrange DNA

The bridge RNA system allows researchers to edit, delete and convert DNA recombinases without using CRISPR

- PMLiVE

GenAI for medical writers is here to stay (and it’s not as scary as we thought)

By Tom Wilson

- PMLiVE

Youth is served

Why are 18-year-olds concerned about healthcare?

- PMLiVE

Joint Clinical Assessments: bureaucratic nightmare, AI opportunity, or both?

By Manca Povsic and Andrew Dobb

Amiculum

Unrivalled Convenience – Perks of Virtual Medical Education

Explore the unrivalled convenience of virtual collaboration in medical education with our new series, "Perks of Virtual Medical Education." Learn why this flexible, efficient mode of learning is the future...

Impetus Digital

- PMLiVE

Novo Nordisk shares positive phase 3 results for Ozempic in diabetes and chronic kidney disease

Approximately 40% of people living with type 2 diabetes will develop CKD

- PMLiVE

AbbVie/Genmab’s Epkinly granted FDA accelerated approval to treat follicular lymphoma

Approximately 15,000 people develop the form of non-Hodgkin lymphoma every year in the US

- PMLiVE

FDA approves Verona’s Ohtuvayre as COPD maintenance treatment in adults

More than 390 million people worldwide are living with COPD and about half of patients experience almost daily symptoms

- PMLiVE

Takeda’s mezagitamab shows promise in immune thrombocytopenia

The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links